Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective

Clinical and Experimental Pharmacology and Physiology

Volumn 29, Issue 11, 2002, Pages 1030-1034

  Green, A Richard ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Animal models; Cerebral; Ischaemia; N methyl D aspartate antagonists; Neuroprotection; NXY 059; Stroke

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; CLOMETHIAZOLE; DISODIUM 4[(TERT BUTYLIMINO)METHYL]BENZENE 1,3 DISULFONATE N OXIDE; GAVESTINEL; LANICEMINE; NEUROPROTECTIVE AGENT; NYX 059; TIRILAZAD; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; HUMAN; MEASUREMENT; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRACTICE GUIDELINE; REPRODUCIBILITY; STROKE; TREATMENT FAILURE;

ANIMALS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPROTECTIVE AGENTS; PATIENT SELECTION;

EID: 0036402443     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2002.03767.x     Document Type: Conference Paper

References (34)

1. Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342-4.
2. Green AR, Cross AJ. Neuroprotective Agents and Cerebral Ischaemia. Academic Press, London. 1997.
3. Wiebers DO, Adams HP, Whisnant JP. Animal models of stroke: Are they relevant to human disease? Stroke 1989; 21: 1-3.
4. Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding pre-clinical neuroprotective and restorative drug development. Stroke 1999; 30: 2752-8.
5. Tatlisumak T, Takano K, Carano RAD, Fisher M. Delayed treatment with an adenosine kinase inhibitor GP683 attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke 1998; 29: 1952-9.
6. Muir KW, Lees KR. Clinical experiences with excitatory amino acid antagonists. Stroke 1995; 26: 503-13.
7. Dawson DA, Wadsworth G, Palmer AM. A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res. 2001; 892: 344-50.
8. Crockard A, Bannotti F, Hunstock AT, Smith RD, Harris RJ, Symon L. Cerebral blood flow and edema following carotid occlusion in the gerbil. Stroke 1980; 11: 494-8.
9. Cross AJ, Jones JA, Snares M, Jostell KG, Bredberg U, Green AR. The protective action of chlormethiazole against ischaemia-induced neuro-degeneration in gerbils when infused at doses having little sedative or anticonvulsant activity. Br. J. Pharmacol. 1995; 114: 1625-30.
10. Longa EZ, Weistein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91.
11. Sydserff SG, Cross AJ, Green AR. The neuroprotective effect of chlormethiazole on ischaemic neuronal damage following permanent middle cerebral artery ischaemia in the rat. Neurodegeneration 1995; 4: 323-8.
12. Mohr JP, Gautier JC, Hier D, Stein RW. Middle cerebral artery. In: Barnett HJM, Stein BM, Mohr JP, Yatsu FM (eds). Stroke. Volume 1: Pathophysiology, Diagnosis and Management. Churchill Livingstone, New York. 1986; 377-450.
13. Ringelstein EB, Biniek R, Weiller C, Ammeling B, Nolte PN, Thron A. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 1992; 42: 289-98.
14. Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat: Studies on dose, plasma concentration and therapeutic time window. Br. J. Pharmacol. 2002; 135: 103-12.
15. Xue D, Slivka A, Buchan AM. Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Stroke 1992; 23: 894-9.
16. Tirilazad International Steering Committee. Tirilazad mesylate in acute ischemic stroke: A systematic review. Stroke 2000; 32: 2257-65.
17. The Ninds t-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995; 333: 1581-7.
18. Brinker G, Franke C, Hoehn M, Uhlenkuken U, Hossmann KA. Thrombolysis of cerebral clot embolism in rat: Effect of treatment delay. Neuroreport 1999; 10: 3269-72.
19. Massieu L, Thedinga KH, McVey M, Fagg GE. A comparative analysis of the neuroprotective properties of competitive and uncompetitive N-methyl-D-aspartate receptor antagonists in vivo: Implications for the process of excitotoxic degeneration and its therapy. Neuroscience 1993; 55: 883-92.
20. Davis SM, Lees KR, Albers GW et al. Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist. Stroke 2000; 31: 347-54.
21. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjo BK. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. 1999; 19: 778-87.
22. Baldwin HA, Jones JA, Cross AJ, Green AR. Histological, biochemical and behavioural evidence for the neuroprotective action of chlormethiazole following prolonged carotid artery occlusion. Neurodegeneration 1993; 2: 139-46.
23. Marshall JWB, Ridley RM. Assessment of functional impairment following permanent middle cerebral artery occlusion in a non-human primate species. Neurodegeneration 1996; 5: 275-86.
24. Marshall JWB, Duffin KJ, Green AR, Ridley RM. NXY-059, a free radical trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001; 32: 190-8.
25. Hudzik TJ, Borrelli A, Bialobok P et al. Long-term functional end points following middle cerebral artery occlusion in the rat. Pharmacol. Biochem. Behav. 2000; 65: 553-62.
26. Dewar D, Yam P, McCulloch J. Drug development for stroke: Importance of protecting cerebral white matter. Eur. J. Pharmacol. 1999; 375: 41-50.
27. Busto R, Dietrich WD, Globus MY, Valdos A, Steinberg P, Ginsberg WD. Small differences in intraischemic brain temperature critically determine the extent of ischemic brain injury. J. Cereb. Blood Flow Metab. 1987; 7: 729-38.
28. Patel PM, Drummond JC, Cole DJ. Induced hypertension during restoration of flow after temporary middle cerebral artery occlusion in the rat. Effect on neuronal injury and edema. Surg. Neurol. 1991; 20: 195-201.
29. Ginsberg MD, Busto R. Rodent models of cerebral ischaemia. Stroke 1989; 20: 1627-42.
30. Sacco RL, DeRosa JT, Haley Jr EC et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: A randomized controlled trial. JAMA 2001; 285: 1719-28.
31. Reggiani A, Pietra C, Arban R et al. The neuroprotective activity of the glycine receptor antagonist GV150526: An in vivo study by magnetic resonance imaging. Eur. J. Pharmacol. 2001; 419: 147-53.
32. Beaulieu C, de Crespigny A, Tong DC, Moseley ME, Albers GW, Marks MP. Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: Evolution of lesion volume and correlation with clinical outcome. Ann. Neurol. 1999; 46: 568-78.
33. Wahlgren NG, Ranasinha KW, Rosolacci T et al. Clomethiazole acute stroke study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Stroke 1999; 30: 21-8.
34. Nilsson D, Wemer J, Nymar L, Björck S, Schulman S. Safety and tolerability of NXY-059 after 8- and 72-hour intravenous infusions of escalating doses in healthy young and elderly volunteers. Cerebrovasc. Dis. 2001; 11 (Suppl. 4): 76 (Abstract).